T cells as mediators of protective immunity against liver stages of Plasmodium

Trends in Parasitology

Volumn 19, Issue 2, 2003, Pages 88-93

  Tsuji, Moriya ^a   Zavala, Fidel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CIRCUMSPOROZOITE ANTIGEN; MALARIA VACCINE; PROTOZOAL PROTEIN; SPOROZOITE VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CELL SPECIFICITY; CELLULAR IMMUNITY; ERYTHROCYTE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOBIOLOGY; IMMUNOREGULATION; LIVER; LYMPHOCYTE FUNCTION; MALARIA; MEDIATOR; NATURAL KILLER CELL; NONHUMAN; PARASITE DEVELOPMENT; PARASITE IMMUNITY; PLASMODIUM; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REGULATORY MECHANISM; REVIEW; SPOROZOITE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ERYTHROCYTES; HUMANS; IMMUNIZATION; LIVER; MALARIA; MALARIA VACCINES; PLASMODIUM; T-LYMPHOCYTE SUBSETS;

ANIMALIA; MUS MUSCULUS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTOZOA;

EID: 0037312371     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4922(02)00053-3     Document Type: Review

References (60)

1. Nussenzweig V., Nussenzweig R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45:1989;283-334.
2. Chen D.H., et al. Immunity to sporozoite-induced malaria infection in mice. I. The effect of immunization of T and B cell-deficient mice. J. Immunol. 118:1977;1322-1327.
3. + T cells and antibodies required for immunity to malaria sporozoites. Nature. 330:1987;664-666.
4. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl Acad. Sci. U.S.A. 85:1988;573-576.
5. + T cells to sporozoite-induced protection against malaria. Immunology. 80:1993;1-5.
6. Romero P., et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature. 341:1989;323-326.
7. + cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Immunol. 3:1991;579-585.
8. Weiss W.R., et al. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J. Immunol. 149:1992;2103-2109.
9. + T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153:1994;4636-4648.
10. Tsuji M., et al. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J. Virol. 72:1998;6907-6910.
11. Khusmith S., et al. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science. 252:1991;715-718.
12. Doolan D.L., et al. Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. J. Biol. Chem. 271:1996;17861-17868.
13. Hill A.V., et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature. 360:1992;434-439.
14. + cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. J. Immunol. 149:1992;966-971.
15. Aidoo M., et al. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet. 345:1995;1003-1007.
16. Wizel B., et al. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J. Immunol. 155:1995;766-775.
17. + CTL epitope in naturally exposed Kenyan adults. Eur. J. Immunol. 27:1997;1952-1957.
18. Connelly M., et al. T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect. Immun. 65:1997;5082-5087.
19. Aidoo M., et al. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infect. Immun. 68:2000;227-232.
20. *01-restricted cytotoxic T-lymphocyte epitope from the Plasmodium falciparum circumsporozoite protein. Infect. Immun. 69:2001;2766-2771.
21. Gilbert S.C., et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science. 279:1998;1173-1177.
22. +) T cells against malaria liver stages. J. Exp. Med. 194:2001;173-180.
23. + T-cell responses against malaria liver stages. Nat. Med. 8:2002;166-170.
24. Scheller L.F., Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl Acad. Sci. U.S.A. 92:1995;4066-4068.
25. + T cell responses to malaria liver stages. Proc. Natl Acad. Sci. U.S.A. 99:2002;11819-11824.
26. Ferreira A., et al. Inhibition of development of exoerythrocytic forms of malaria parasites by γ interferon. Science. 232:1986;881-884.
27. + cell-, interferon γ-, and nitric oxide-dependent immunity. J. Exp. Med. 183:1996;1739-1746.
28. Renggli J., et al. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol. 19:1997;145-148.
29. + T cells in the Plasmodium yoelii model. J. Immunol. 163:1999;884-892.
30. + T cells. J. Immunol. 164:2000;2009-2015.
31. + T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18:2000;275-308.
32. + T cells by exogenous cell-associated antigens. Immunity. 17:2002;211-220.
33. Krzych U., et al. The role of intrahepatic lymphocytes in mediating protective immunity induced by attenuated Plasmodium berghei sporozoites. Immunol. Rev. 174:2000;123-134.
34. Guidotti L.G., et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl Acad. Sci. USA. 91:1994;3764-3768.
35. Hill A.V., et al. DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy. Dev. Biol. 104:2000;171-179.
36. Doolan D.L., Hoffman S.L. DNA-based vaccines against malaria: status and promise of the multi-stage malaria DNA vaccine operation. Int. J. Parasitol. 31:2001;753-762.
37. +) T cells. Virology. 280:2001;155-159.
38. Romero P.J., et al. Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei. Eur. J. Immunol. 18:1988;1951-1957.
39. Krzych U., et al. Distinct T-cell specificities are induced with the authentic versus recombinant Plasmodium berghei circumsporozoite protein. J. Immunol. 148:1992;2530-2538.
40. Good M.F., et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc. Natl Acad. Sci. U.S.A. 85:1988;1199-1203.
41. + clones from a malaria-immunized volunteer. Science. 246:1989;1603-1606.
42. Herrera S., et al. Human recognition of T cell epitopes on the Plasmodium vivax circumsporozoite protein. J. Immunol. 148:1992;3986-3990.
43. Zevering Y., et al. Life spans of human T cell responses to determinants of circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. Proc. Natl Acad. Sci. U.S.A. 91:1994;6118-6122.
44. Calvo-Calle J.M., et al. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J. Immunol. 159:1997;1362-1373.
45. Molano A., et al. Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses. J. Immunol. 164:2000;5005-5009.
46. Good M.F., et al. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science. 235:1987;1059-1062.
47. Tam J.P., et al. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 171:1990;299-306.
48. Sinnis P., Nardin E. Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein. Chem. Immunol. 80:2002;70-96.
49. + cytolytic T cell clone confers protection against murine malaria. J. Exp. Med. 172:1990;1353-1357.
50. + T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein. Exp. Parasitol. 84:1996;223-230.
51. + T cell clones against Plasmodium yoelii liver stages. J. Immunol. 150:1993;1471-1478.
52. Valmori D., et al. Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. Eur. J. Immunol. 24:1994;1458-1462.
53. + T cell- and IFN-γ-dependent elimination of infected hepatocytes. J. Immunol. 157:1996;4061-4067.
54. +) T-cell- and γ interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein. Infect. Immun. 67:1999;5604-5614.
55. Tsuji M., et al. γδ T cells contribute to immunity against the liver stages of malaria in αb T-cell-deficient mice. Proc. Natl Acad. Sci. U.S.A. 91:1994;345-349.
56. McKenna K.C., et al. γδ T cells are a component of early immunity against preerythrocytic malaria parasites. Infect. Immun. 68:2000;2224-2230.
57. Schofield L., et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science. 283:1999;225-229.
58. Romero J.F., et al. CD1d-restricted NK T cells are dispensable for specific antibody responses and protective immunity against liver stage malaria infection in mice. Parasite Immunol. 23:2001;267-269.
59. Gonzalez-Aseguinolaza G., et al. α-galactosylceramide-activated Vα 14 natural killer T cells mediate protection against murine malaria. Proc. Natl Acad. Sci. U.S.A. 97:2000;8461-8466.
60. Gonzalez-Aseguinolaza G., et al. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195:2002;617-624.